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To the Editor: Tuberculosis (TB) is out of control in Africa. More 
ominous is the increasing resurgence of multidrug-resistant (MDR-
TB) and extensively drug-resistant TB (XDR-TB), reported in 2006 
after the outbreak in KwaZulu-Natal, South Africa.1 Studies have 
confirmed the prior existence of XDR-TB in several countries.2,3 The 
prevalence of XDR-TB since 2002 and its associated poor treatment-
related outcomes were also documented in several provinces of 
South Africa.4 These data indicate that the overall culture conversion 
rates, independent of HIV status, were less than 20%.4,5 Many of 
these patients subsequently reverted their culture status. XDR-TB 
in South Africa is therefore difficult to treat and many patients are 
therapeutically destitute.
Some hope is in sight with the impending arrival of new anti-
TB drugs such as TMC 207 and OPC67683.6,7 However, there is 
increasing concern that these drugs will lose their efficacy with time 
because of increasing drug-specific resistance emerging. Cogent 
public health strategies must be put in place to prevent emerging 
drug resistance. Better planning of such a strategy requires a clearer 
understanding about the temporal genesis of drug resistance relative 
to the introduction of a drug within a specific public health context. 
For further insight into this question we sought to establish the 
earliest record of XDR-TB (based on the current World Health 
Organization (WHO) definition) in the Western Cape province, 
relative to the introduction of MDR-TB treatment in 1985. Such data 
also inform on the evolution of XDR-TB as a specific disease entity, 
and the environmental and host factors driving drug resistance.
Methods
Subjects were retrospectively identified from the MDR-TB records of 
all patients attending the Brooklyn Chest Hospital before December 
2002 after approval from the University of Cape Town Health Sciences 
Faculty Research Ethics Committee. Brooklyn Chest Hospital was 
then the central management centre for all drug-resistant TB cases 
in the Cape Metropole.8 Patient outcomes and prevalence of XDR-TB 
from 2003 to 2007 in the Western Cape region of South Africa have 
been reported elsewhere.4 Sputum culture and sensitivity data were 
extracted from reference laboratory reports. Patients were defined as 
having XDR-TB if they were resistant to rifampicin and isoniazid in 
addition to having resistance to a fluoroquinolone and at least one 
aminoglycoside.
Results
There were ~2 919 MDR-TB cases treated in the Cape Metropole 
region of the Western Cape province from 1990 to 2002 (inclusive) 
where data were available. Patient data before 1990 were not 
available. A total of 48 patients met the criteria for XDR-TB (32 HIV-
uninfected, 2 HIV-infected, and 14 who refused testing or whose HIV 
result was unavailable). After the introduction of MDR-TB treatment 
in the Western Cape in 1985 - 1987, the first documented case that 
we found was recorded in June 1992. As a group the patients were 
young (median age 34.3 years, range 15 - 59 years); the average weight 
at diagnosis was 46.7 kg (standard deviation 10.6 kg); 54.2% (26/48) 
were female; and 77.1% (37/48) were of mixed ancestry. 
Table I shows drug sensitivity testing profiles. Patients were 
not tested for sensitivity to para-aminosalicylic acid (PAS)  or 
capreomycin and so none received appropriate XDR-TB-specific 
treatment (capreomycin or PAS) at the time.
Most subjects had their MDR-TB treatment continued but with 
the addition of clofazamine in 19 patients and thiacetazone in 7. Two 
patients had their MDR treatment withdrawn after the diagnosis of 
XDR-TB. Outcome data were incomplete, as 28 patients were lost to 
follow-up. Of the remaining 20 patients, 18 died within a mean of 
10.8 months (range 1 - 32 months) from the time of diagnosis.
Discussion
We show that XDR-TB (using the 2006 revised definition) was 
prevalent in the Cape Metropole area of the Western Cape as early 
as 1992, ~5 - 7 years after the introduction of MDR-TB treatment in 
this region in 1985 and following the diagnosis of the first MDR-TB 
cases.9,10 There was therefore a lag period of ~5 - 7 years, as far as 
we can tell, before the first passively detected XDR-TB cases were 
diagnosed. Similarly, MDR-TB was recognised in the mid-1980s in 
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There are limited data on the temporal relationship between the 
regional introduction of multidrug-resistant tuberculosis (MDR-
TB) treatment and the subsequent development of extensively drug-
resistant TB (XDR-TB). The first XDR-TB case in the Western Cape 
province of South Africa was recorded in 1992, approximately 5 - 7 
years after the regional introduction of MDR-TB-like treatment. 
Between 1990 and 2002 we identified 48 patients with XDR-TB in 
the Cape Metropole region of the Western Cape province. Patients 
were predominantly HIV-uninfected and median survival was 10.8 
months. XDR-TB has therefore been present in the Western Cape 
at least since 1992. These data inform public health policy relevant 
to the introduction of new anti-TB drug regimens. 
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the Western Cape ~9 years after the widespread use of rifampicin 
in this area. Resistance in almost all cases was probably acquired, as 
all the patients had prior MDR-TB treatment. Given these findings 
increased public health awareness and vigilance will be required, 
with appropriate targeting of treatment and withdrawal in those 
at high risk of amplifying resistance, when newer drugs such as 
TMC 207 are introduced into clinical practice.11 Several strategies, 
including the use of fixed-dose combination tablets, should be 
considered to minimise erratic use of individual drugs.12,13 If such 
strategies are not strictly enforced, our data indicate that within ~7 
years widespread resistance is likely to emerge.
XDR-TB was invariably fatal despite almost all tested patients 
being HIV-uninfected. This is in keeping with recent reports in 
South Africa4,14 indicating the prevalence of highly virulent strains, 
and dispels the notion that XDR-TB in Africa is almost exclusively 
associated with HIV-related attenuated host immunity. 
Survival in some patients, despite lack of appropriate treatment, 
was as long as 32 months. These data therefore reaffirm the urgent 
need to build community stay and palliative care facilities in 
high-burden settings to prevent ongoing disease transmission in 
therapeutically destitute patients.
Our study has several limitations including biases inherent in the 
retrospective study design, including missing data; selection and 
treatment bias; and patients lost to follow-up. As data were only 
available from 1990, the presence of XDR-TB before this date could 
not be ascertained. Furthermore, drug susceptibility testing in the 
Western Cape in the early 1990s was not standardised and many cases 
may have been missed, or patients may have died before reaching 
health services. Patients could also have been misdiagnosed and 
treated elsewhere in the province despite Brooklyn Chest Hospital 
being the designated treatment facility. It is therefore likely that 
we have underestimated the prevalence of XDR-TB before 2002. 
It is also not clear whether these cases were acquired or due to 
primary transmission of disease. However, our main objective was to 
establish temporality rather than document incidence, outcomes or 
transmission dynamics.
In summary, without strengthening the full spectrum of the health 
care system from access to rapid diagnostics through to improved 
laboratory capacity, and appropriate protection of new drugs through 
strict control policies, we are likely to face the emergence of even 
more extensively drug-resistant TB within several years as each new 
agent is brought to the market. 
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Table I. Resistance patterns for MDR-TB patients meeting  
current WHO XDR-TB definitions  
Drug sensitivity testing*
Drug No. tested No. resistant (%)
Rifampicin 48 48 (100)
Isoniazid 48 48 (100)
Ofloxacin 48 48 (100)
Kanamycin 50 35 (70.0)
Streptomycin 48 41 (85.4)
Amikacin 32 8 (25.0)
Ethionamide 46 13 (28.3)
Thiacetazone 46 33 (71.7)
Ethambutol 46 25 (54.3)
Cycloserine 37 13 (35.1)
Pyrazinamide 2 2 (100)
*No patients were tested for sensitivity to PAS or capreomycin. Capreomycin and drug sensi-
tivity testing to capreomycin were not available in South Africa before 2006/2007.
